

FORMPTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY SCKET NUMBER PU3556USW	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>09/830037</b>	
INTERNATIONAL APPLICATION NO. <b>PCT/GB99/03472</b>		INTERNATIONAL FILING DATE <b>20 October 1999</b>		PRIORITY DATE CLAIMED <b>22 October 1998</b>	
TITLE OF INVENTION <b>FLUTICASONE LOTION HAVING IMPROVED VASOCONSTRICTOR ACTIVITY</b>					
APPLICANT(S) FOR DO/EO/US <b>Gordon J. DOW; Keith Arthur JOHNSON; Frances Furr KELLY; Robert William LATHROP; Rukmini RAJAGOPALAN</b>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 35 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol> <p><b>Items 13 to 20 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail</li> <li>23. <input checked="" type="checkbox"/> Other items or information:  <div style="margin-left: 20px;"> Copy of PCT Request (Form PCT/RO/101)  Copy of PCT Publication cover  Copy of Correction to PCT Request before 30th Month </div> </li> </ol>					



09/830037

JC02 Rec'd PCT/PTO 20 APR 2001

## CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR

Applicant(s): Gordon J. DOW et al.

Docket No.

PU3556USW

Serial No.

371 of PCT/GB99/03472

Filing Date

Examiner

Group Art Unit

Invention: FLUTICASONE LOTION HAVING IMPROVED VASOCONSTRICTOR ACTIVITY


I hereby certify that this 35 USC 371 PATENT APPLICATION with corresponding papers  
(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  
37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.

20231-0001 on April 20 2001  
(Date)

Elaine Martens

(Typed or Printed Name of Person Mailing Correspondence)



(Signature of Person Mailing Correspondence)

41EL395942518US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

Via Facsimile

**Correction to PCT  
Request before 30th  
Month**

TO:  
PCT Examination  
International Bureau of WIPO  
34 Chimin des Colombettes  
1211 Geneva 20  
Switzerland

Fax: 011 41 22 740 1435

Applicant's File Reference

**PU3556WO**

International Application No.  
**PCT/GB99/03472**

30th Month Deadline: **22 April 2001**

Applicant

**Glaxo Group Limited**

International Filing Date:  
**20 October 1999**

Title: **Fluticasone Lotion Having Improved  
Vasoconstrictor Activity**

**Correction:**

**Please make the following correction to PCT Request PCT/GB99/03472 filed on 20 October 1999.**

**-Please change address of inventors/applicants: Keith Arthur JOHNSON; Frances Furr KELLY; Robert William LATHROP and Rukmini RAJAGOPALAN to:**

GlaxoSmithKline  
c/o Corporate Intellectual Property Department  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709

Please acknowledge receipt of this request by return fax to (919) 483-7988 in the United States.  
If there should be questions, please call (919) 483-2252.

Thank you.

Sincerely,



Christopher P. Rogers  
Attorney for Applicant